Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Time to Transit Recovery After Naloxegol in Cardiac Surgery Intensive Care Trial
2020-000087-26Phase 3Completed
- Sponsor
- CMC Ambroise Paré
- Start
- Feb 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of naloxegol in postoperative ileus (POI) and functional gastrointestinal disorder (FGID), sponsored by CMC Ambroise Paré. Primary endpoint: Time to transit recovery. Started Feb 2020; status: completed.
02
Drugs
naloxegol
03
Conditions
postoperative ileus (POI)functional gastrointestinal disorder (FGID)
Beyond the preview
Go deeper on 2020-000087-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000087-26.